Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Mercian Corporation

Yoshiharu Mizui

Satoshi Yamamoto

Masanori Fujita

Jean-Christophe P Harmange

Mark Spyvee

Kenzo Muramoto

Yoshiyuki Kawakami

Kiyoshi Okamoto

Seiichi Kobayashi

Tomohiro Matsushima

Naoki Yoneda

Makoto Kotake

Hiroshi Shirota

Hong Du

Kenichi Chiba

Isao Tanaka

Fabian Gusovsky

Masaki Goto

Yoshikazu Kuboi

John (Yuan) Wang

Hideki Sakurai

Yoshihito Eguchi

Akifumi Kimura

Takatoshi Kawai

Yong-Chun Shen

Megumi Kawada

Mitsuo Nagai

Yoshihiko Kotake

Jun Niijima

Takashi Nakashima

Ping Zhu

Roch Boivin

Peter G Smith

Toshio Tsuchida

Yimin Jiang

Silvia Buonamici

Xiang-Yi Li

Kazuyuki Dobashi

Masashi Yoshida

Lihua Yu

Toshimitsu Uenaka

Tomohiro Sameshima

Naoto Kawamura

Susumu Takeda

Takao Yamori

Michael W Seiler

Naoki Asai

Jesse Chow

Motoko Matsufuji

Takashi Sakai

Charles-André Lemelin

Eunice Sun Park

Kian Huat Lim

Jacob D Feala

Tomonari Yamada

Suguru Suzuki

Naoko Nagaoka

Shinji Yoshitake

Akifumi Okuda

Koji Norihisa

Masao Iwata

Kumiko Kishi

Keisuke Komeda

Marco Peter Fekkes

Toshio Seto

Ray Wood

Hiroyuki Kato

Noboru Suzuki

John Wang

Atsushi Inoue

John (yuan) Wang

Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.

Splice variants associated with neomorphic SF3B1 mutants

The present invention provides methods for the use of compounds having formula (I) in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R-R, t, X, Y, Z, and n are as defined herein.

Macrocyclic compounds useful as pharmaceuticals

The present invention provides compositions comprising compounds having formula (I): 

The present invention provides compounds having formula (I): 

The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution ofsp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it. 

Bioactive substance

The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution ofsp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it

Physiologically active substances

A novel human antithrombin III (AT III) mutant having a high antithrombin activity in the absence of heparin and effective in the treatment of thrombotic disorders as an anticoagulant, which is obtained by mutating amino acids at the reactive site and the heparin binding site of human AT III into another amino acids with the use of the recombinant DNA technology with the use of a DNA coding for AT III as a template. The invention also relates to a method for mass producing the above-described mutant by incubating a host transformed by an expression vector having the cDNA of the mutant inserted therein.

Human antithrombin III mutants

Growing community of inventors

Tsukuba, Japan

Yoshiharu Mizui